- Conference Call Scheduled for Thursday, November 3, 2016 at 4:30pm
NEWARK, Calif.--(BUSINESS WIRE)--
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing botulinum toxin products for use in aesthetic and therapeutic
indications, today announced that the company will release third quarter
2016 financial results on Thursday, November 3, 2016 after the close of
market. Revance will host a corresponding conference call and a
live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the
results and provide a business and pipeline update.
Individuals interested in listening to the conference call may do so by
dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for
international callers and reference conference ID: 96279951; or from the
webcast link in the investor relations section of the company's website
A replay of the call will be available beginning November 3,
2016 at 5:00pm PT/8:00pm ET to November 4, 2016 at 5:00pm PT/8:00pm ET.
To access the replay, dial (855) 859-2056 or (404) 537-3406 and
reference conference ID: 96279951. The webcast will be available in the
investor relations section on the company's website for 30 days
following the completion of the call.
About Revance Therapeutics, Inc.
Revance, a Silicon Valley-based biotechnology company, is committed to
the advancement of remarkable science. The company is developing a
portfolio of products for aesthetic medicine and underserved therapeutic
specialties, including dermatology and neurology. Revance's science is
based upon a proprietary TransMTS® peptide technology, which when
combined with active drug molecules, may help address current unmet
Revance's initial focus is on developing daxibotulinumtoxinA, the
company's highly purified botulinum toxin, for a broad spectrum of
aesthetic and therapeutic indications, including facial wrinkles and
muscle movement disorders. The company's lead drug candidate,
DaxibotulinumtoxinA for Injection (RT002), is currently in development
for the treatment of glabellar lines and cervical dystonia and has the
potential to be the first long-acting neurotoxin. The company holds
worldwide rights for all indications of RT002 injectable and RT001
topical and the pharmaceutical uses of the TransMTS technology platform.
More information on Revance may be found at www.revance.com.
"Revance Therapeutics", TransMTS®, "Remarkable Science Changes
Everything", and the Revance logo are registered trademarks of Revance
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024005850/en/
Jeanie Herbert, (714) 325-3584
Ami Bavishi, (212) 213-0006
Nadine Tosk, (504) 453-8344
Source: Revance Therapeutics, Inc.
News Provided by Acquire Media